Ontology highlight
ABSTRACT: Introduction
Chronic breathlessness is highly prevalent and distressing to patients and families. No medication is registered for its symptomatic reduction. The strongest evidence is for regular, low-dose, extended- release (ER) oral morphine. A recent large phase III study suggests the subgroup most likely to benefit have chronic obstructive pulmonary disease (COPD) and modified Medical Research Council breathlessness scores of 3 or 4. This protocol is for an adequately powered, parallel-arm, placebo-controlled, multisite, factorial, block-randomised study evaluating regular ER morphine for chronic breathlessness in people with COPD.Methods and analysis
The primary question is what effect regular ER morphine has on worst breathlessness, measured daily on a 0-10 numerical r
SUBMITTER: Currow D
PROVIDER: S-EPMC5726102 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature